Document is current
Any future updates will be listed below
-
Authors
Grove, Erik Lerkevang
Skjøth, Flemming http://orcid.org/0000-0003-2975-647X
Nielsen, Peter Brønnum
Christensen, Thomas Decker
Larsen, Torben Bjerregaard
- License Information
-
More Information
Article History
Received: 2 July 2018
Accepted: 1 October 2018
First Online: 25 October 2018
Competing Interests
: The authors report the following general conflicts: E.L.G. has received speaker honoraria or consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and Roche. T.B.L. has served as an investigator for Janssen Scientific Affairs, L.L.C. and Boehringer Ingelheim and has been on the speaker bureaus for Bayer, BMS/Pfizer, Roche Diagnostics, Takeda and Boehringer Ingelheim. T.D.C. has been on the speaker bureaus for AstraZeneca, Boehringer-Ingelheim, Pfizer, Roche Diagnostics, Takeda and Bristol-Myers Squibb and has been in an Advisory Board for Bayer and Merck Sharp & Dohme (MSD). PBN has received speaker honaria from Boehringer Ingelheim and BMS/Pfizer, consulting fees from Bayer and Daiichi-Sankyo and grant support from BMS/Pfizer. FS has received consulting fees from Bayer.
